High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes

Bone Marrow Transplantation

Volumn 20, Issue 11, 1997, Pages 931-937

  Bearman, S I ^a   Overmoyer, B A ^b   Bolwell, B J ^b   Taylor, C W ^c   Shpall, E J ^a   Cagnoni, P J ^a   Mechling, B E ^a   Ronk, B ^a   Baron A E ^d   Purdy, M H ^a   Ross, M ^a   Jones, R B ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Dose intensive therapy; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOTRANSPLANTATION; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; RELAPSE; STEM CELL; STEM CELL TRANSPLANTATION; THORAX WALL;

EID: 0030777815     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701000     Document Type: Article

References (30)

1. Early breast cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15, 71-85.
2. Eder JP, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
3. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1375.
4. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
5. Antman K, Ayash L, Elias A el al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
6. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
7. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
8. Jones SE, Moon TE, Bonadonna G et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. Am J Clin Oncol 1987; 10: 387-395.
9. Dimitrov N, Anderson S, Fisher B et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: findings from NSABP B-22. Proc ASCO 1994; 13: 64 (Abstr. 58).
10. + hematopoietic progenitor cells into breast cancer patients following high-dose chemotherapy: influence of cell source and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
11. Jones RB, Matthes S, Shpall EJ et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmaco-dynamic evaluation of carmustine. J Natl Cancer Inst 1993; 85: 640-647.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observatons. J Am Stat Assoc 1958; 53: 457-481.
13. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991; 9: 2134-2140.
14. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternative doxorubicin and CMF regimens in breast cancer with more than 3 positive nodes. Ten year results. J Am Med Assoc 1995; 273: 542-547.
15. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585-594.
16. Frei E III, Teicher B, Holden SA et al. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417-6423.
17. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential antitumor agents. XIII. On the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Chemother Rep 1964; 35: 1-111.
18. Frei E III, Antman K, Teicher B et al. Bone marrow autotransplantation for solid tumors. Prospects. J Clin Oncol 1989; 4: 515-526.
19. Schabel FM Jr, Trader NW, Laster WR Jr et al. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiotics Chemother 1978; 23: 200-215.
20. Frei E III, Cucchi CA, Rosowsky A et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 1986; 82: 2158-2162.
21. Schabel FM Jr. Synergism and antagonism among antitumor agents. In: The Pharmacological Basis of Cancer Chemotherapy. Williams and Wilkins: Baltimore, 1975, pp 595-623.
22. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
23. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162-1170.
24. Sheridan WP, Begley CG, Juttner CA. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
25. Ayash L, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
26. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
27. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
28. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colony-stimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high dose chemotherapy. Blood 1993; 81: 2031-2035.
29. Bolwell BJ, Goormastic M, Yanssens T et al. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bone Marrow Transplant 1994; 14: 913-918.
30. Hudis C, Seidman A, Raptis G et al. Sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) in women (pts) with resected breast cancer and greater than or equal to 4 (+) lymph nodes (LN): preliminary results. Proc ASCO 1995; 14: 113 (Abstr. 152).